Researchers from the Chinese Academy of Medical Sciences and Peking Union Medical College reported on the development of a novel EDB-FN-targeted Gd-based contrast agent, named EDB-Gd-DOTA-Cy7, for imaging and treatment planning of pancreatic ductal adenocarcinoma (PDAC).
The FDA has cleared C4 Therapeutics Inc.’s IND application for CFT-8919, an orally bioavailable Bidac (bifunctional degradation activating compound) degrader designed to be potent and selective against EGFR L858R for non-small-cell lung cancer (NSCLC).
It has been previously demonstrated that the WNT gene/protein family member WNT5A is down-regulated in leukemia, and low expression of this tumor suppressor has been correlated with disease progression and poor prognosis. In a recent study, researchers from Universidade Estadual de Campina aimed to assess the role of WNT5A in leukemia and evaluate the effects of Foxy-5, (Wntresearch AB) a WNT5A-mimicking compound, on the progression of this disease.
China’s Center for Drug Evaluation has cleared Jacobio Pharmaceuticals Group Co. Ltd.’s KRAS G12C inhibitor, glecirasib (JAB-21822), to begin a phase III pivotal study for pancreatic cancer.
Sinotau Pharmaceutical Group raised ¥1.1 billion (US$152 million) in a financing round to develop its radiopharmaceutical drugs for diagnostic and therapeutic interventions.
Privately held F-star Therapeutics Inc. and Takeda Pharmaceutical Co. Ltd. have completed their third license agreement, one that could bring F-star about $1 billion. The new collaboration is focused on R&D against undisclosed cancer targets.
Most drug developers working in the immunotherapy space focus on existing therapeutic targets when developing cancer drugs, optimizing ways of drugging them via engineering modalities such as CAR T-cell approaches, CRISPR editing or antibody-drug conjugates that deliver toxic payloads. The angle of one company – Cartography Biosciences – is the opposite to this. Its modus operandi is to pinpoint the immunological targets first, leveraging tools that already exist, before building therapies around them.
South Korean pharmaceutical giant Yuhan Corp. gained Korea’s MFDS approval to expand indications for its potent oral third-generation tyrosine kinase inhibitor Leclaza (lazertinib) as a first-line treatment for EGFR T790M mutation-positive non-small-cell lung cancer (NSCLC).
IPSirius SAS, an early stage French immuno-oncology firm, hopes to obtain a clinical trial authorization from the U.K.’s Medicines and Healthcare Regulatory Products Agency next year, to enable it to move its novel therapeutic cancer vaccine into a first-in-human trial in patients with non-small-cell lung cancer.
Pretzel Therapeutics Inc. has patented heterocycle-containing compounds acting as Lon protease homolog, mitochondrial (LONP1) inhibitors. They are reported to be useful for the treatment of cancer, aging, neurodegeneration and metabolic diseases.
RSS
.webp?height=488&t=1670008838&width=650 "Acute myeloid leukemia")
